Zacks: Analysts Anticipate Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) to Announce -$0.48 Earnings Per Share

Analysts forecast that Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSAGet Rating) will post earnings of ($0.48) per share for the current quarter, Zacks reports. Two analysts have made estimates for Kiniksa Pharmaceuticals’ earnings. The highest EPS estimate is ($0.45) and the lowest is ($0.50). Kiniksa Pharmaceuticals reported earnings per share of ($0.61) during the same quarter last year, which suggests a positive year over year growth rate of 21.3%. The business is scheduled to report its next earnings report on Monday, January 1st.

On average, analysts expect that Kiniksa Pharmaceuticals will report full year earnings of ($1.82) per share for the current year, with EPS estimates ranging from ($2.05) to ($1.58). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.40) per share, with EPS estimates ranging from ($1.55) to ($1.25). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Kiniksa Pharmaceuticals.

Kiniksa Pharmaceuticals (NASDAQ:KNSAGet Rating) last released its earnings results on Tuesday, May 3rd. The company reported ($0.36) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.52) by $0.16. During the same quarter in the prior year, the company earned ($0.72) EPS.

Separately, Zacks Investment Research raised shares of Kiniksa Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, April 27th.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KNSA. Lazard Asset Management LLC bought a new position in Kiniksa Pharmaceuticals in the 4th quarter worth approximately $44,000. Macquarie Group Ltd. lifted its stake in Kiniksa Pharmaceuticals by 1,207.2% in the 3rd quarter. Macquarie Group Ltd. now owns 4,353 shares of the company’s stock worth $50,000 after purchasing an additional 4,020 shares in the last quarter. BNP Paribas Arbitrage SA lifted its stake in Kiniksa Pharmaceuticals by 424.5% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 5,633 shares of the company’s stock worth $64,000 after purchasing an additional 4,559 shares in the last quarter. Rockefeller Capital Management L.P. lifted its stake in Kiniksa Pharmaceuticals by 666.7% in the 4th quarter. Rockefeller Capital Management L.P. now owns 5,750 shares of the company’s stock worth $67,000 after purchasing an additional 5,000 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Kiniksa Pharmaceuticals by 290.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,164 shares of the company’s stock worth $84,000 after purchasing an additional 5,327 shares in the last quarter. 42.57% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals stock opened at $9.89 on Monday. Kiniksa Pharmaceuticals has a twelve month low of $9.03 and a twelve month high of $16.68. The firm has a 50 day moving average price of $10.28 and a 200-day moving average price of $11.35. The company has a market capitalization of $683.44 million, a P/E ratio of -4.30 and a beta of 0.03.

Kiniksa Pharmaceuticals Company Profile (Get Rating)

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

Featured Stories

Get a free copy of the Zacks research report on Kiniksa Pharmaceuticals (KNSA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kiniksa Pharmaceuticals (NASDAQ:KNSA)

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.